This week: the 2026 ACC/AHA Dyslipidemia Guideline, the Ez-PAVE head-to-head target trial, VESALIUS-CV upstream primary prevention data, and the world's first oral PCSK9 inhibitor to pass Phase 3. The science on LDL is not just settled — it is accelerating. The deniers didn't get the memo. Allow me to deliver it.

The causal relationship between LDL-C — and more precisely, ApoB-containing lipoprotein particles — and ASCVD is one of the most thoroughly validated findings in medicine. The CTT Collaboration pooled 170,000+ individuals across 26 statin trials: each 1.0 mmol/L reduction in LDL-C conferred a ~21% reduction in major vascular events, irrespective of age, sex, baseline LDL, or prior vascular history. Individuals with PCSK9 loss-of-function gene variants carry lifelong LDL in the 30–40 mg/dL range with no adverse consequences — and dramatically fewer heart attacks. Patients with heterozygous familial hypercholesterolemia demonstrate the dose-response from the other direction: lifelong high LDL, premature atherosclerosis, and dramatic risk reduction with treatment. Nature ran the trial. The result was unambiguous.

The 2017 EAS Consensus Statement by Ference et al. applied a formal Bradford Hill causality framework to LDL across multiple Bradford Hill criteria — including plausibility, biological gradient, consistency, and mechanistic specificity — and graded every single one Class 1, synthesizing 200+ studies, 2 million participants, and 150,000 cardiovascular events. The conclusion: LDL is not a biomarker. It is a cause. And critically, the benefit of lowering LDL is mechanism-independent: statins, ezetimibe, PCSK9 inhibitors, bile acid sequestrants, and ileal bypass surgery all produce the same proportional risk reduction per mmol/L LDL-C lowered (I² = 0%). The effect tracks the LDL. Not the drug.

LDL exposure is also cumulative. Mendelian randomization studies show up to a threefold greater proportional risk reduction from lifelong lower LDL versus short-term statin treatment started after atherosclerosis has developed. Five years of therapy: ~22% risk reduction per mmol/L. Forty years: ~54%. Every untreated year is compounding atherogenic burden. The visualization below makes this arithmetic visible. The science delivered the verdict. The 2026 guidelines translated it into action.

The 2026 Blumenthal et al. guideline — endorsed by eleven professional societies — officially retires the 2018 guidance and brings back explicit LDL-C numeric targets stratified by risk. This matters: it gives clinicians and patients something concrete to aim for and legitimizes intensification when targets aren't met.

For patients with established ASCVD, the guideline sets a goal of <55 mg/dL (non-HDL-C <85 mg/dL) for most — particularly those at very high risk. The therapeutic cascade is now explicit: high-intensity statin → ezetimibe → PCSK9 mAb or bempedoic acid → inclisiran, sequentially or in combination until target is met. The days of "the statin is enough" are over.

One target not yet reflected in the 2026 ACC/AHA framework but worth noting for clinicians who follow international literature: the 2025 ESC/EAS Focused Update introduced an extreme risk category — patients experiencing recurrent vascular events on maximally tolerated statin-based therapy, or those with polyvascular disease — with a Class IIb LDL-C goal of <40 mg/dL. That is a number most U.S. clinicians would consider extraordinary. It is where the evidence is pointing. It will not be the last time we see the floor move lower.

Here is a question that has lingered in cardiology for years: we know lower LDL-C is better than not treating at all — but is <55 mg/dL actually better than <70 mg/dL in secondary prevention? Until now, the evidence rested largely on observational data, Mendelian randomization, and indirect comparisons across trials. We have always been inferring the target, not testing it directly.

The Ez-PAVE trial answered this directly. In this open-label, superiority trial conducted in South Korea, 3,048 patients with established ASCVD were randomized 1:1 to a target LDL-C of <55 mg/dL versus <70 mg/dL. The primary endpoint was a composite of cardiovascular death, nonfatal MI, nonfatal stroke, any revascularization, or hospitalization for unstable angina at 3 years.

The difference in achieved LDL-C between groups was only 10 mg/dL — yet that translated to a 33% relative risk reduction and a 3.1% absolute risk difference (NNT ~32 over 3 years). For a target adjustment. Ez-PAVE removes the inferential burden from the secondary prevention LDL target — no more extrapolating from trial-to-trial comparisons. We have a direct randomized comparison showing <55 mg/dL produces meaningfully better outcomes than <70 mg/dL in the same trial. The 2026 guidelines were drafted before Ez-PAVE published. The next revision will likely make that target incontrovertible.

Legitimate limitations: open-label design, single-country (South Korea), and the intensive arm achieved a median of 56 mg/dL — slightly above target — underscoring real-world attainment challenges. PCSK9 inhibitors were used in only 2.3% of participants; 39.2% never reached <55 mg/dL. The trial proved the target is worth hitting. It also proved we don't know how to hit it at scale. Ez-PAVE tells us where to aim in secondary prevention. The next question is when to start — and the 2026 guidelines push the answer upstream.

The guideline adopts PREVENT-ASCVD risk equations (replacing Pooled Cohort) for adults aged 30–79. Categories: low (<3%), borderline (3–<5%), intermediate (5–<10%), high (≥10%). The "CPR" model guides decisions: Calculate risk, Personalize with risk-enhancers (hsCRP, Lp(a), ABI, CAC), and Reclassify with imaging when uncertain. Lp(a) measurement at least once in all adults is now Class I. HIV adults aged 40–75 on stable antiretrovirals carry a Class I statin indication for primary prevention.

CAC scoring gets its most explicit guideline architecture yet: CAC ≥100 AU triggers a Class I recommendation for LDL-lowering to <70 mg/dL; CAC ≥1000 AU triggers a <55 mg/dL target — placing these patients in the secondary prevention range.

Published in JAMA — March 28, 2026. This prespecified subgroup of VESALIUS-CV enrolled 3,655 patients meeting the strictest definition of "no significant atherosclerosis": no prior revascularization, no arterial stenosis ≥50%, no CAC ≥100. Every patient had high-risk diabetes. All were on background statin therapy (84%), most high-intensity. Randomized to evolocumab 140 mg biweekly or placebo. Median follow-up: 4.8 years.

Under current guidelines, these patients would not have qualified for a PCSK9 inhibitor. No MI. No stroke. No known plaques. Yet the data is unambiguous. The Kaplan-Meier curves separated after year 1 — consistent with early event prevention, before clinical atherosclerosis had fully declared itself. The exploratory all-cause mortality signal (HR 0.76) is not confirmable by trial hierarchy — but it is not dismissible either. The caveats are real: this is a prespecified subgroup of high-risk individuals with diabetes, not a dedicated primary prevention trial. But the conclusion is clear: PCSK9 inhibitors are not a post-event rescue therapy. They are a preventive intervention. The wall between primary and secondary prevention is more permeable than the guidelines have acknowledged.

At 96 weeks, the median achieved LDL-C in the evolocumab arm was 44 mg/dL — squarely in secondary prevention target territory, in patients with no known atherosclerosis. The case for a unified <55 mg/dL target across all high-risk individuals, regardless of where they sit on the atherosclerosis continuum, is becoming increasingly hard to dismiss.

VESALIUS-CV extends the benefit upstream, before the first event. CORALreef asks whether we can now deliver it orally.

Published in the New England Journal of Medicine, February 2026. Enlicitide decanoate — an oral macrocyclic peptide PCSK9 inhibitor — was tested in 2,909 participants on background statin therapy, randomized 2:1 to enlicitide 20 mg daily or placebo for 52 weeks.

The LDL reduction — ~57% on top of background statin — matches injectable PCSK9 monoclonal antibodies exactly. Same mechanism. Different delivery. And that changes everything downstream. Injectable PCSK9 inhibitors have been available since 2015; fewer than 1% of ASCVD patients in the U.S. are taking them. That treatment gap is a scandal. An oral agent with equivalent efficacy and a placebo-like safety profile could meaningfully close it.

But the CORALreef story at ACC.26 didn't stop there. The CORALreef AddOn trial — presented this week — ran a head-to-head comparison that no one in the field should overlook. In 301 patients on stable statin therapy, enlicitide was randomized against the three most widely used oral non-statin add-on therapies: bempedoic acid alone, ezetimibe alone, and bempedoic acid plus ezetimibe combined. At 56 days, enlicitide produced a 64.6% LDL-C reduction — greater than every comparator by a margin that was not subtle. And when it came to actually reaching guideline targets, the gap was extraordinary: 78.2% of enlicitide patients reached LDL-C <55 mg/dL with ≥50% reduction, compared to 20% on bempedoic acid plus ezetimibe combined — the current best available oral regimen.

The Lp(a) finding deserves special notice. While enlicitide reduced Lp(a) by 26%, all three comparators — bempedoic acid, ezetimibe, and their combination — actually increased Lp(a) levels (by 8–10%). Lp(a) is now a Class I-measured risk factor under the 2026 guidelines, and for patients with elevated Lp(a), the choice of add-on therapy matters beyond LDL-C alone.

Enlicitide does not yet have a cardiovascular outcomes trial. CORALreef Outcomes (14,500+ patients, projected completion December 2029) will deliver that. Until then, the benefit is inferred from LDL-lowering magnitude and class effect. I am confident it will follow the biology. But I'll label that what it is — see the box below.

These arguments arrive in clinic weekly. Here's how to answer them.

"Statins cause muscle damage and should be avoided." True myopathy occurs in ~0.1% on standard doses. Rhabdomyolysis is rarer still. Myalgias in blinded rechallenge trials approach the nocebo-attributed rate. For genuine intolerance, bempedoic acid now carries a Class I, Level B recommendation from the 2025 ESC/EAS (CLEAR Outcomes, 13,970 patients, 13% MACE reduction). The side effects are real; the therapeutic goal is not invalidated. It redirects to a different tool.

"LDL-C is a surrogate." As the Ference 2017 data already showed: the benefit tracks the LDL, not the drug. Hard outcomes confirm this — FOURIER: 20% reduction in CV death/MI/stroke (key secondary endpoint); ODYSSEY OUTCOMES: 29% reduction in all-cause mortality in the highest-risk ACS patients (prespecified subgroup).

"I need cholesterol for my brain / hormones / cell membranes." Endogenous cholesterol synthesis is maintained regardless of pharmacologic manipulation. PCSK9 loss-of-function variant carriers with lifelong LDL in the 30–40 mg/dL range show no cognitive deterioration, hormonal dysfunction, or cellular pathology. EBBINGHAUS-OLE confirms long-term cognitive safety with PCSK9 inhibition. They just have dramatically fewer heart attacks.

And the cognitive safety argument now runs further than just 'no harm.' A 2026 real-world analysis by Novak et al. — 838,217 propensity score-matched adults with dyslipidemia across 72 U.S. health systems — found statin use associated with a 31% lower risk of incident Alzheimer's disease (RR 0.69; 95% CI, 0.62–0.75) and lower all-cause mortality. The association held across both early- and late-onset AD subtypes, was robust on 3-year lagged sensitivity analysis, and was not explained by competing mortality risk. Hydrophilic statins (rosuvastatin, pravastatin) showed a modestly greater protective effect than lipophilic agents in direct head-to-head comparison. No dose-response gradient was observed — being on a statin at all, rather than the dose, appears to be the relevant factor for cognitive risk modification. The 'statins damage my brain' argument was already empirically thin. It is now inverted.

"I take fish oil / red yeast rice — that's enough." The 2025 ESC/EAS Focused Update issued a Class III recommendation (formally not recommended) against dietary supplements for ASCVD risk reduction. The SPORT trial randomized participants to low-dose rosuvastatin versus six commonly used supplements. At 28 days, the statin produced significant LDL-C reduction. Not one supplement did. See the box below.

Patients who distrust statins often come from genuine concern — pharma influence, polypharmacy, feeling like a number. Those concerns deserve engagement. What they don't deserve is to go untreated while LDL silently builds in their coronary arteries until a plaque ruptures without warning.

1. Measure Lp(a) in every adult — at least once. The 2026 guidelines make this Class I. Most patients have never had it checked. This is a gap we can close immediately.

2. Established ASCVD + LDL-C ≥55 mg/dL on a statin: the question is not "should we add something" — it is "which agent, in what order." Ez-PAVE just RCT-validated <55 mg/dL as a target that produces a 33% MACE reduction versus <70 mg/dL. Ezetimibe is cheap and underused. PCSK9 inhibitors are increasingly accessible. Enlicitide, if approved, may become the preferred next step for the oral-first patient.

3. High-risk diabetes, primary prevention, LDL-C ≥100 mg/dL on high-intensity statin: VESALIUS-CV changed the calculus. Benefits accrue after year one. A mortality signal exists (HR 0.76, exploratory). The case for early PCSK9 inhibitor use in this population is no longer speculative.

4. Use CAC scoring. Borderline-risk patient reluctant to start a statin? CAC is guideline-supported, often reimbursable, and decisional. CAC = 0 can safely defer therapy. CAC ≥300 changes the conversation dramatically — and ≥1000 triggers a <55 mg/dL target equivalent to secondary prevention.

5. ACS admission: initiate or intensify lipid therapy before discharge. ESC/EAS 2025 Class I. For treatment-naive ACS patients unlikely to reach target on statin alone, start statin + ezetimibe combination at admission — Class IIa. The first 100 days post-MI carry a 10% incidence of second event. Waiting until the 6-week follow-up is not defensible practice.

6. Start early. Treat to target. The biology compounds in two directions now. Every untreated year accumulates atherogenic burden. And per Novak et al. 2026, it may also represent a year of foregone neuroprotection. Every untreated year is one you cannot undo.

The guidelines are the most actionable in a decade. The tools exist. The evidence is settled. What remains is clinical will — and the discipline to not let misinformation stand between our patients and the treatments that will save their lives.

REFERENCES

1. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Circulation. 2026;153:e00–e00. DOI: 10.1161/CIR.0000000000001423

2. Navar AM, Mikhailova E, Catapano AL, et al. A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide. N Engl J Med. 2026;394:529–539. DOI: 10.1056/NEJMoa2511002 (CORALreef Lipids)

3. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (FOURIER). N Engl J Med. 2017;376:1713–1722. DOI: 10.1056/NEJMoa1615664

4. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (ODYSSEY OUTCOMES). N Engl J Med. 2018;379:2097–2107. DOI: 10.1056/NEJMoa1801174

5. Cholesterol Treatment Trialists (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681. DOI: 10.1016/S0140-6736(10)61350-5

6. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264–1272. DOI: 10.1056/NEJMoa054013

7. Zimerman A, O'Donoghue ML, Ran X, et al. Long-Term Cognitive Safety of Achieving Very Low LDL Cholesterol with Evolocumab (EBBINGHAUS-OLE). NEJM Evid. 2025;4(1):EVIDoa2400112. DOI: 10.1056/EVIDoa2400112

8. Lee YJ, Lee SJ, Kim JW, et al., for the Ez-PAVE Investigators. Ez-PAVE Trial: Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease. N Engl J Med. 2026. DOI: 10.1056/NEJMoa2600283

9. Marston NA, Bohula EA, Bhatia AK, et al. Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Prespecified Subgroup Analysis of VESALIUS-CV. JAMA. Published online March 28, 2026. DOI: 10.1001/jama.2026.3277

10. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459–2472. DOI: 10.1093/eurheartj/ehx144

11. Mach F, Koskinas KC, Roeters van Lennep JE, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2025;46:4359–4378. DOI: 10.1093/eurheartj/ehaf190

12. Catapano AL, Mikhailova E, Navar AM, et al. Efficacy and Safety of Enlicitide Decanoate Compared With Bempedoic Acid, Ezetimibe, or Bempedoic Acid Co-administered With Ezetimibe in Statin-Treated Adults With Hypercholesterolemia: Phase 3 CORALreef AddOn Trial. Presented at ACC.26, March 2026.

13. Laffin LJ, Bruemmer D, Garcia M, et al. Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory Biomarkers (SPORT). J Am Coll Cardiol. 2023;81(1):1–12. DOI: 10.1016/j.jacc.2022.10.013

14. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients (CLEAR Outcomes). N Engl J Med. 2023;388:1353–1364. DOI: 10.1056/NEJMoa2215024

15. Novak DA, Saleem N, Gerhardt PC, et al. Alzheimer's disease in patients prescribed statins: A real-world data analysis of U.S. patient health records. J Alzheimers Dis. 2026;110(3):1474–1489. DOI: 10.1177/13872877261424220